68 - Regulatory Review: What the FDA Expects (S5E8)

This episode focuses on understanding the expectations of the FDA during the regulatory review process for new drug applications. We explore the key data points and presentation formats that meet these expectations, highlighting the importance of clearly demonstrating the drug's safety and effectiveness. We delve into the concepts of pharmacokinetics (PK) and pharmacodynamics (PD) and how they provide crucial information about the drug's behavior in the body. We discuss the importance of bioanalytical method validation to ensure the accuracy and precision of drug concentration measurements. Join us as we demystify the FDA review process and provide insights into what regulators look for in a successful submission.This episode further explores the FDA's focus on Chemistry, Manufacturing, and Controls (CMC) information, emphasizing the importance of consistent drug production at a high standard of quality. We discuss the regulations surrounding manufacturing facilities, equipment, personnel, and processes, as well as the critical aspects of packaging and labeling to prevent errors and ensure patient safety. We also touch upon the role of Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) in ensuring the quality and reliability of preclinical and manufacturing data. We delve into the review process itself, including the different types of FDA meetings that companies can have throughout the drug development process. Finally, we discuss the implications of complete response letters (CRLs) and the value of learning from FDA-published review and approval letters. Tune in for a comprehensive understanding of how to navigate the regulatory review process and meet FDA expectations.